Rosiglitazone alleviates α-naphthylisothiocyanate-induced intrahepatic cholestasis in mice - The role of circulating 15d-PGJ2 and Nogo.
Intrahepatic cholestasis is mainly caused by dysfunctions of molecules for bile secretion with limited treatment. Rosiglitazone is a synthetic ligand while 15-deoxy-Δ12,14 -prostaglandin J2 (15d-PGJ2 ) is the endogenous agonist of PPARγ. Reticulon 4B (Nogo-B) is the detectable Nogo protein family member in the liver and secreted into circulation. Herein, we determined if rosiglitazone can alleviate intrahepatic cholestasis in mice. Wild type, hepatocyte-specific PPARγ or Nogo-B knockout mice received intragastric administration of α-naphthylisothiocyanate (ANIT) and/or rosiglitazone, followed by determination of intrahepatic cholestasis and the involved mechanisms. Serum samples were collected from PBC patients and non-PBC controls to analyze cholestasis-related serum parameters. Rosiglitazone prevented wild type but not hepatocyte-specific PPARγ deficient mice from ANIT-induced intrahepatic cholestasis by activating expression of bile homeostatic molecules, reducing hepatic necrosis, and correcting abnormal serum parameters and bile enterohepatic circulation. Nogo-B deficiency had similar protections to rosiglitazone. ANIT-induced intrahepatic cholestasis reduced 15d-PGJ2 but increased Nogo-B in serum, and both were corrected by rosiglitazone. Nogo-B deficiency in the liver boosted 15d-PGJ2 production, thereby activating expression of PPARγ and bile homeostatic molecules. Rosiglitazone and Nogo-B deficiency also alleviated cholestasis-associated dyslipidemia. Furthermore, reduced 15d-PGJ2 and increased Nogo-B in PBC patients' serum were determined, with a negative or positive correlation to classical cholestatic parameters. In addition, rosiglitazone reduced symptoms of the established intrahepatic cholestasis. Our study demonstrates that 15d-PGJ2 and Nogo are important biomarkers for intrahepatic cholestasis. Synthetic PPARγ ligands can be used for treatment of intrahepatic cholestasis and cholestasis-associated dyslipidemia potentially.